Publication
Article Metrics
Citations
Online attention
Interactions of GFAP with ceftriaxone and phenytoin: SRCD and molecular docking and dynamic simulation
DOI:
10.1016/j.bbagen.2016.04.021
Authors:
Paolo
Ruzza
(CNR-ICB-PD)
,
Rosa Maria
Vitale
(Institute of Biomolecular Chemistry of CNR)
,
Rohanah
Hussain
(Diamond Light Source)
,
Barbara
Biondi
(CNR-ICB-PD)
,
Pietro
Amodeo
(Institute of Biomolecular Chemistry of CNR)
,
Gianpietro
Sechi
(Medical School, University of Sassari)
,
Giuliano
Siligardi
(Diamond Light Source)
Co-authored by industrial partner:
No
Type:
Journal Paper
Journal:
Biochimica Et Biophysica Acta (bba) - General Subjects
State:
Published (Approved)
Published:
May 2016
Diamond Proposal Number(s):
8034

Abstract: GFAP is the major intermediate filament protein in mature astrocytes. Its increased expression and aggregation was firstly associated to Alexander's disease, and successively in different neurological diseases including scrapie, Alzheimer's and Creutzfeld–Jacob diseases. Recently, ceftriaxone a multi-potent β-lactam antibiotic able to overcome the blood–brain barrier, successfully eliminated the cellular toxic effects of misfolded mutated GFAP, similarly to phenytoin sodium, in a cellular model of Alexander's disease and inhibited α-synuclein aggregation protecting PC12 cells from the exposure to 6-hydroxydopamine.
Journal Keywords: Ceftriaxone; Glial fibrillary acidic protein; Neurodegenerative diseases; Synchrotron radiation circular dichroism spectroscopy
Diamond Keywords: Alexander's Disease
Subject Areas:
Medicine,
Biology and Bio-materials
Instruments:
B23-Circular Dichroism
Added On:
08/06/2016 11:43
Discipline Tags:
Neurodegenerative Diseases
Health & Wellbeing
Neurology
Biophysics
Drug Discovery
Life Sciences & Biotech
Technical Tags:
Spectroscopy
Circular Dichroism (CD)